Market Overview

Aegis Capital Downgrades Alcobra Following Q3 Results


On Monday, analysts at Aegis Capital downgraded shares of Alcobra Ltd (NASDAQ: ADHD) from Buy to Hold without a price target.

Yi Chen stated, "In view of the uncertainty from the FDA as to whether Alcobra can submit an NDA with data from one additional Phase 3 adult ADHD trial and data from the ongoing Phase 2b adolescent ADHD trial, we are downgrading the stock.”

In addition, "Given the fact that Alcobra Ltd. does not have revenue and is currently unprofitable, we use a discounted cash flow-based approach to value the shares. Potential price target could come from our estimate of a risk-adjusted net present value (rNPV) for the firm's pipeline based on a comparables analysis. We currently assume that the firm has roughly 17 million shares outstanding at end-2015 and will need to raise additional capital during 2015."

Shares of Alcobra closed Monday’s session at $3.45, down 5.74 percent.

Latest Ratings for ADHD

Oct 2017WBB SecuritiesUpgradesHoldSpeculative Buy
Feb 2017Roth CapitalUpgradesNeutralBuy
Jan 2017JefferiesDowngradesBuyHold

View More Analyst Ratings for ADHD
View the Latest Analyst Ratings


Related Articles (ADHD)

View Comments and Join the Discussion!

Posted-In: Aegis Capital Corporation yi chenAnalyst Color Downgrades Analyst Ratings

Latest Ratings

DEBMO CapitalMaintains400.0
PRITruist SecuritiesMaintains165.0
SHAKJP MorganMaintains70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at